Evotec receives € 3 million payment from Sanofi
Evotec achieves third milestone in cell therapy diabetes alliance with Sanofi
This milestone was triggered after Evotec met pre-agreed critical criteria within the beta cell replacement therapy programme. The ultimate goal of the collaboration is to develop a beta cell replacement therapy for people with diabetes based on beta cells derived from human induced pluripotent stem cells.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are extremely pleased with the progress we are making on this beta cell therapy approach which has the potential to restore beta cell function and, thereby, address the root cause of diabetes rather than only its symptoms.”
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.